检索结果-南通市图书馆

Designing healthy communities： A walkability analysis of LEED-ND

Frontiers of Architectural Research 2016年第4期5卷 433-452页

作者： Adriana A. Zuniga-Teran Barron J. Orr Randy H. Gimblett Nader V. Chalfoun Scott B. Going David P. Guertin Stuart E. marsh Udall Center for Studies in Public Policy University of Arizona Tucson AZ 85719 USA

Prevailing city design in many countries has created sedentary societies that depend on automobile use. Consequently, architects, urban designers, and land planners have developed new urban design theories, which have been incorporated into the Leadership in Energy and Environmental Design for Neighborhood Development （LEED-ND） certification system. The LEED- ND includes design elements that improve human well-being by facilitating walking and biking, a concept known as walkability. Despite these positive developments, relevant research findings from other fields of study have not been fully integrated into the LEED-ND. According to Zuniga-Teran （2015）, relevant walkability research findings from multiple disciplines were organized into a walkability framework （WF） that organizes design elements related to physical activity into nine categories, namely, connectivity, land use, density, traffic safety, surveil- lance, parking, experience, greenspace, and community. In this study, we analyze walkability in the LEED-ND through the lens of the nine WF categories. Through quantitative and qualitative analyses, we identify gaps and strengths in the LEED-ND and propose potential enhancements to this certification system that reflects what is known about enhancing walkability more comprehensively through neighborhood design analysis. This work seeks to facilitate the translation of research into practice, which can ultimately lead to more active and healthier societies.

关键词： Watkabitity LEED-ND Physical activity Urban design Well-being Built environment

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

高速电路设计采用自动化工具如虎添翼

引用

电子设计技术 2003年第5期10卷 62+64-66+68页

作者： David marsh

到目前为止,典型的设计环境不过是指将原理图转换成印制电路板的一些软件工具。然而,当今的高速电路已迫使软件工具进一步解决定时问题和信号完整性问题,因为这两个问题会严重影响整个产品的设计。

关键词：印制电路板高速设计印刷电路板(材料) 印制线元件布局设计约束信号完整性分析布线程序拓扑结构数据结构设计师原理图混合信号

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Hepatitis C virus treatment with glecaprevir and pibrentasvir in patients co-prescribed carbamazepine:Three case reports

引用

World Journal of Gastrointestinal Pharmacology and Therapeutics 2023年第4期14卷 33-38页

作者： Michael Braude Dilip T Ratnam Louise marsh Joshua H Abasszade Anouk T Dev Department of Gastroenterology and Hepatology Monash HealthClayton 3168VICAustralia General Practice Margaret River Medical CentreMargaret River 6285Australia

BACKGROUND Highly effective and well-tolerated direct-acting antiviral(DAA)therapies have revolutionised the management of hepatitis C virus(HCV);however,niche populations face treatment *** co-prescribed with several firstgeneration anti-epileptic drugs(AEDs)are contraindicated due to drug-drug interactions.A common example is carbamazepine whereby steady-state carbamazepine reduces the maximum concentration and area under the curve of velpatasvir,glecaprevir and pibrentasvir due to potent cytochrome P450(CYP)3A4 *** also induces P-glycoprotein which reduces glecaprevir and pibrentasvir’s area under curve to infinite *** and glecaprevir-pibrentasvir are contraindicated in patients who are co-prescribed carbamazepine due to the risk of reduced DAA therapeutic effect and consequently,virological treatment *** presents a challenge for patients in whom carbamazepine substitution is medically unfeasible,impractical or ***,the properties of current generation DAA therapies,including high-potency non-structural protein 5A inhibitory effect,may be sufficient to overcome reduced bioavailability arising from carbamazepine related CYP 3A4 and P-glycoprotein *** SUMMARY We present a case series of three patients with non-cirrhotic,treatment-naïve,genotype 1a,1b,and 3a HCV who were treated with a 12 wk course of glecaprevir-pibrentasvir,while co-prescribed carbamazepine for seizure ***-pibrentasvir combination therapy was chosen due to its potent in vitro activity and low barrier to pan-genotypic resistance associated *** therapy was dose-separated from carbamazepine to maximise time to peak concentration,and taken with meals to improve *** virological response at 12 wk was achieved in each patient with no adverse *** DAA therapies,including glecaprevir-pibrentasvir,warrant consideration as a therapeutic agent in people with HCV w

关键词： Antiepileptic drugs Drug interactions Hepatitis C virus Sustained virological response Health care access Case repor

来源：

维普期刊数据库评论